Overview

A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors

Status:
Active, not recruiting

Trial end date:
2021-08-01

Target enrollment:

Participant gender:

Summary

A Phase 1 dose escalation study to determine if SNDX-6352 as monotherapy and SNDX-6352 in combination with a fixed dose of durvalumab will be sufficiently safe and well-tolerated at biologically active doses to warrant further investigation in patients with solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Syndax Pharmaceuticals

Treatments:

Durvalumab